Intrasplenic vaccination against experimental melanoma

International Journal of Oncology

Volumn 9, Issue 1, 1996, Pages 123-129

  Shrayer, David ^a   Park, Cho Hyun ^a   Kouttab, Nicolas ^a   Bogaars, Hendrix ^a   McInnis, Renee ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

intrasplenic vaccination; melanoma immunity

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; VACCINATION;

EID: 0029973637     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.1.123     Document Type: Article

References (4)

1. Shrayer D, Gersten DM, Koness J, Maizel A, Wanebo H and Hearing VJ: B700 antigen as a component of an antimelanoma vaccine: formalinized extracellular antigens. Pigment Cell Res 5: 107-112, 1992.
2. Shrayer D, Koness J, Bogaars H, Maizel A and Wanebo H: Prevention of tumor growth and metastases of B16 melanoma with formalinized extracellular antigens (fECA) vaccination. FASEB J 5: 51-52, 1991.
3. Shrayer D, Koness J, Kouttab N, Bogaars H, Hearing VJ, Gersten DM, Maizel A and Wanebo H: Preimmunization of mice with formalinized extracellular antigens of melanoma in combination with IL-2 and surgical resection increased survival and tumor control in metastatic melanoma model. J Surg Oncol 52: 142-149, 1993.
4. DeLeo AB, Hearing VJ, Vieira WD and Law LW: Serological characterization of a shared melanoma-associated antigen of mouse melanomas. Relationship to the B700 glycoprotein. Melanoma Res 1: 133-140, 1991.